UAE: RAK’s Julphar boosted by Covid vaccine contract

Issue 1125 - 06 May 2021

The return to financial health of Ras Al-Khaimah (RAK)’s Gulf Pharmaceutical Industries (Julphar) is likely to be aided by a contract to produce the Covid-19 vaccine developed by Sinopharm China National Biotec Group and Abu Dhabi-based Group 42. The latter is linked to national security adviser Sheikh Tahnoun Bin Zayed.

Want to read more?

Small article


(Access to one 100-400 word article)

Subscribe to Gulf States Newsletter

View subscription options

Don't have an account?

Register for access to our free content

An account also allows you to view selected free articles and set up news alerts.


Want to see more articles like this?

Search our archive or set up custom notifications to be alerted about new content.

Have you created a free account?

Sign up for an account to set up news alerts and get free access to our historic archive (1979-2003), articles under 100 words, Gulf States Newsletter View articles and a selection of other samples.

View a selection of Free articles

Follow us on Google News